INHIBITORS OF INFLUENZA VIRUSES REPLICATION
1 Assignment
0 Petitions
Accused Products
Abstract
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
5 Citations
186 Claims
-
1-156. -156 (canceled)
- 157. A method of inhibiting the replication or reducing the number of influenza viruses in a biological sample or in a patient comprising administering to said biological sample or patient an effective amount of a compound of Formula (IA):
-
165. The compound of claim 165, wherein:
-
R1 is —
H;R2 is —
H or —
CH2OH;R3 is —
H, —
F, or —
Cl;Z1 is —
H, —
F, or —
Cl;Z2 is —
H;Z3 is —
H;R5 is independently; i) —
H orii) a C1-C6-alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1C4 alkyl, —
O(C1-C4 alkyl), —
NH2, —
NH(C1-C4 alkyl), —
N(C1-C4 alkyl)2, —
C(O)(C1-C4 alkyl), —
OC(O)(C1-C4 alkyl), —
(O)O(C1-C4 alkyl), —
CO2H, —
C3-C7 non-aromatic carbocycle, 4-8 membered non-aromatic heterocycle, phenyl, and 5-6 membered heteroaryl;wherein each of said alkyl groups referred to in the substituents of the C1-C6 alkyl group represented by R5 is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, —
NH2, —
NH(C1-C4 alkyl), —
N(C1-C4 alkyl)2, —
OCO(C1-C4 alkyl), —
CO(C1-C4 alkyl), —
CO2H, —
CO2(C1-C4 alkyl), and C1-C4 alkoxy; andwherein each of said carbocycle, phenyl, heterocycle, and heteroaryl referred to in the substituents of the C1-C6 alkyl group represented by R5 is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, —
NH2, —
NH(C1-C4 alkyl), —
N(C1-C4 alkyl)2, —
OCO(C1-C4 alkyl), —
CO(C1-C4 alkyl), —
CO2H, —
CO2(C1-C4 alkyl), and —
C1-C4 alkoxy.
-
- 172. A method of treating influenza infection in a patient comprising administering to said patient an effective amount of a compound of Formula (IA):
Specification